UBS O'Connor’s Apyx Medical APYX Stock Holding History

UBS O'Connor’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-85,000	Closed	-$498K	–	961
2022 Q2	$498K	Buy	+85,000	New	+$436K	0.01%	815

Other funds holding APYX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Invenire Partners Ridgefield, Connecticut $65.4M AUM 18.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

UBS O'Connor's APYX Position: Q3 2022 in Review

UBS O'Connor sold out of Apyx Medical (APYX) in Q3 2022, closing a stake of 85,000 shares — an estimated $498K sold.

UBS O'Connor first reported a position in APYX in Q2 2022 and held it in 1 quarter. The position peaked at $498K in Q2 2022. 54 funds tracked by Wall St. Rank hold APYX as of Q3 2022.

UBS O'Connor reported no remaining Apyx Medical position as of Q3 2022 after selling out during the quarter.
UBS O'Connor sold 85,000 Apyx Medical shares in Q3 2022, an estimated $498K.
UBS O'Connor first reported a position in Apyx Medical in Q2 2022 and held it in 1 quarter.
UBS O'Connor's Apyx Medical position peaked at $498K in Q2 2022.
54 funds tracked by Wall St. Rank held Apyx Medical as of Q3 2022.

Based on UBS O'Connor's 13F filing for Q3 2022, filed 14 Nov 2022.